Show simple item record

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial

dc.contributor.authorHeath, Paul T
dc.contributor.authorGaliza, Eva P
dc.contributor.authorBaxter, David Neil
dc.contributor.authorBoffito, Marta
dc.contributor.authorBrowne, Duncan
dc.contributor.authorBurns, Fiona
dc.contributor.authorChadwick, David R
dc.contributor.authorClark, Rebecca
dc.contributor.authorCosgrove, Catherine A
dc.contributor.authorGalloway, James
dc.contributor.authorGoodman, Anna L
dc.contributor.authorHeer, Amardeep
dc.contributor.authorHigham, Andrew
dc.contributor.authorIyengar, Shalini
dc.contributor.authorJeanes, Christopher
dc.contributor.authorKalra, Philip A
dc.contributor.authorKyriakidou, Christina
dc.contributor.authorBradley, Judy M
dc.contributor.authorMunthali, Chigomezgo
dc.contributor.authorMinassian, Angela M
dc.contributor.authorMcGill, Fiona
dc.contributor.authorMoore, Patrick
dc.contributor.authorMunsoor, Imrozia
dc.contributor.authorNicholls, Helen
dc.contributor.authorOsanlou, Orod
dc.contributor.authorPackham, Jonathan
dc.contributor.authorPretswell, Carol H
dc.contributor.authorFrancisco Ramos, Alberto San
dc.contributor.authorSaralaya, Dinesh
dc.contributor.authorSheridan, Ray P
dc.contributor.authorSmith, Richard
dc.contributor.authorSoiza, Roy L
dc.contributor.authorSwift, Pauline A
dc.contributor.authorThomson, Emma C
dc.contributor.authorTurner, Jeremy
dc.contributor.authorViljoen, Marianne Elizabeth
dc.contributor.authorFries, Louis
dc.contributor.authorCho, Iksung
dc.contributor.authorMcKnight, Irene
dc.contributor.authorGlenn, Greg
dc.contributor.authorRivers, E Joy
dc.contributor.authorRobertson, Andreana
dc.contributor.authorAlves, Katia
dc.contributor.authorSmith, Kathy
dc.contributor.authorToback, Seth
dc.date.accessioned2024-02-07T08:18:43Z
dc.date.available2024-02-07T08:18:43Z
dc.date.issued2023-02-01
dc.identifier219934148
dc.identifier4ac58f0a-eaec-44cf-8b0f-606231528539
dc.identifier36210481
dc.identifier85147388710
dc.identifier.citationHeath , P T , Galiza , E P , Baxter , D N , Boffito , M , Browne , D , Burns , F , Chadwick , D R , Clark , R , Cosgrove , C A , Galloway , J , Goodman , A L , Heer , A , Higham , A , Iyengar , S , Jeanes , C , Kalra , P A , Kyriakidou , C , Bradley , J M , Munthali , C , Minassian , A M , McGill , F , Moore , P , Munsoor , I , Nicholls , H , Osanlou , O , Packham , J , Pretswell , C H , Francisco Ramos , A S , Saralaya , D , Sheridan , R P , Smith , R , Soiza , R L , Swift , P A , Thomson , E C , Turner , J , Viljoen , M E , Fries , L , Cho , I , McKnight , I , Glenn , G , Rivers , E J , Robertson , A , Alves , K , Smith , K & Toback , S 2023 , ' Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial ' , Clinical Infectious Diseases , vol. 76 , no. 3 , pp. 398-407 . https://doi.org/10.1093/cid/ciac803en
dc.identifier.issn1058-4838
dc.identifier.otherORCID: /0000-0002-1397-4272/work/121059556
dc.identifier.urihttp://aura-test.abdn.ac.uk/handle/2164/20093
dc.descriptionAcknowledgements The study and article were funded by Novavax. We would like to thank all the study participants for their commitment to this study. We also acknowledge the investigators and their study teams for their hard work and dedication. In addition, we would like to thank the National Institute for Health Research, representatives from the Department of Health and Social Care laboratories and NHS Digital and the members of the UK Vaccine Task Force. Editorial support was provided by Kelly Cameron of Ashfield MedComms, an Inizio company Funding This work was funded by Novavax, and the sponsor had primary responsibility for study design, study vaccines, protocol development, study monitoring, data management, and statistical analyses. All authors reviewed and approved the manuscript before submission. LF reports a position as a prior full-time employee, now contractor to Novavax re-imbursed hourly for work performed on this study and in analyses and drafting this report. IC reports providing medical writing support for this work as an employee of Novavaxen
dc.format.extent10
dc.format.extent1042287
dc.language.isoeng
dc.relation.ispartofClinical Infectious Diseasesen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectCoVID-19en
dc.subjectImmunogenicityen
dc.subjectAsymptomatic Infectionsen
dc.subjectSARS-CoV-2en
dc.subjectVaccine efficacyen
dc.subjectR Medicineen
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleSafety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trialen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.contributor.institutionUniversity of Aberdeen.Ageing Clinical & Experimental Research Teamen
dc.description.statusPeer revieweden
dc.identifier.doihttps://doi.org/10.1093/cid/ciac803
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85147388710&partnerID=8YFLogxKen
dc.identifier.vol76en
dc.identifier.iss3en


Files in this item

Thumbnail
Name:
Mark_etal_EHJ_Major_Cardiovasc ...
Size:
2.977Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record